In the UKGTS (United Kingdom Glaucoma Treatment Study), the primary outcome measure used to demonstrate that latanoprost significantly reduces glaucoma progression compared to placebo was:

• A Mean deviation slope on standard automated perimetry
• B Rate of retinal nerve fiber layer thinning on OCT
• C Optic disc cupping progression by stereophotography
• D Time to visual field deterioration ✓

Explanation

The UKGTS was the first placebo-controlled RCT to show that IOP-lowering treatment (latanoprost) reduces the rate of visual field deterioration in glaucoma. The primary endpoint was time to visual field deterioration, defined as statistically significant progression on standard automated perimetry. This trial established level-1 evidence for treatment benefit in glaucoma management.

Reference: Khurana Comprehensive Ophthalmology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.